Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915628 | 0.89 | ALDH1A1 (0.43) | ALDH1A1TSHRPRKAA1KDRPDGFRB | |
| SCHEMBL15132782 | 0.85 | ALDH1A1 (0.67) | ALDH1A1TSHRPRKAA1KDRPDGFRB | |
| SCHEMBL19442393 | 0.79 | ALDH1A1 (0.55) | ALDH1A1TSHRPRKAA1KDRPDGFRB | |
| SCHEMBL22803232 | 0.79 | ALDH1A1 (0.50) | ALDH1A1TSHRPRKAA1KDRPDGFRB | |
| SCHEMBL5921880 | 0.78 | L3MBTL1 (0.57) | ALDH1A1TSHRKDRPDGFRBFGFR1 | |
| SCHEMBL12118142 | 0.76 | KDR (0.50) | ALDH1A1TSHRPRKAA1KDRPDGFRB | |
| SCHEMBL24336951 | 0.76 | ALDH1A1 (0.52) | ALDH1A1TSHRPRKAA1KDRPDGFRB | |
| SCHEMBL3133167 | 0.75 | IGF1R (0.43) | ALDH1A1TSHRHPGDPOLB | |
| SCHEMBL1044420 | 0.75 | KDR (0.59) | ALDH1A1PRKAA1KDRPDGFRBFGFR1 | |
| SCHEMBL28146850 | 0.74 | NPSR1 (0.56) | ALDH1A1RAB9ANPSR1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501962-B2 | Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt | NATCO PHARMA LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-8501962-B2 | Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt | NATCO PHARMA LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| WO-2012059941-A1 | PROCESS FOR PREPARATION OF SUNITINIB MALATE AND SALTS THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2012-05-10 | — | — | WO | disclosed |
| US-20110092717-A1 | PROCESS FOR THE PREPARATION OF HIGH PURITY SUNITINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | NATCO PHARMA LIMITED (IN) | 2011-04-21 | — | — | US | disclosed |
| US-20110092717-A1 | PROCESS FOR THE PREPARATION OF HIGH PURITY SUNITINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | NATCO PHARMA LIMITED (IN) | 2011-04-21 | — | — | US | disclosed |
| EP-2264027-A1 | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | Ratiopharm GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| EP-2264027-A1 | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | Ratiopharm GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010136458-A1 | PROCESS FOR THE PREPARATION OF N-[2-DIETHYLAMINO)ETHYL]-5-[(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE | RATIOPHARM GMBH (DE) | 2010-12-02 | — | — | WO | disclosed |
| US-20090062368-A1 | DEUTERIUM-ENRICHED SUNITINIB | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20060009510-A1 | Method of synthesizing indolinone compounds | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062368-A1 | DEUTERIUM-ENRICHED SUNITINIB | SRMS, KDR, ABL1 | ALDH1A1 4139/4885TSHR 2364/4885PRKAA1 2655/4885 |
| US-20060009510-A1 | Method of synthesizing indolinone compounds | HCCS, ALDH18A1, MKI67 | ALDH1A1 319/4885TSHR 2968/4885PRKAA1 935/4885 |
| US-20110092717-A1 | PROCESS FOR THE PREPARATION OF HIGH PURITY SUNITINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | MET, RCC2, MDH2 | ALDH1A1 783/4885TSHR 3898/4885PRKAA1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.